Data supports and describes the ongoing Phase 1a/b clinical trial of IK-175 as a single agent and in combination with nivolumab in advanced solid tumors
Study evaluates IK-175 in urothelial carcinoma patients including AHR positive enriched subpopulation
Read more at globenewswire.com